Supernus Pharmaceuticals reported $1.18M in Interest Expense on Debt for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Abbott ABT:US USD 86M 46M
Aerie Pharmaceuticals AERI:US USD 1.65M 12K
Ani Pharmaceuticals ANIP:US USD 7.26M 595K
Aurora Cannabis Inc ACB:CN CAD 10.57M 4.2M
Bristol Myers Squibb BMY:US USD 299M 14M
Canopy Growth Corp WEED:CN CAD 30.47M 3.57M
Eli Lilly And LLY:US USD 81.5M 300K
Endo International Ordinary Shares ENDP:US USD 74.93M 65M
Lannett LCI:US USD 15.03M 222K
Marinus Pharmaceuticals MRNS:US USD 2.63M 22K
Pacira Pharmaceuticals PCRX:US USD 9.86M 1.02M
Pfizer PFE:US USD 311M 18M
Revance Therapeutics RVNC:US USD 6.92M 3.04M
Teva Pharmaceutical Industries TEVA:US USD 230M 5M
United Therapeutics UTHR:US USD 9.2M 3M